PCAS - Net sales as of September 30, 2019
04 Novembre 2019 - 5:45PM
PCAS - Net sales as of September 30, 2019
NET SALES AS OF SEPTEMBER 30, 2019
Longjumeau, November 4, 2019
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its net sales as of September 30, 2019.
The PCAS Group had generated consolidated net
sales of €145.6 million as of September 30, 2019, up 1.0%
compared to the same period during the previous financial year
(-0.3% at a constant exchange rate).
In millions of euros |
|
2019 |
|
2018 |
|
% change |
|
2019 At a constant exchange
rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
Net sales as of 30
September |
|
145.6 |
|
144.2 |
|
1.0% |
|
143.8 |
|
-0.3% |
Pharmaceutical Synthesis |
|
89.1 |
|
88.9 |
|
0.2% |
|
87.7 |
|
-1.4% |
Fine Specialty Chemicals |
|
56.5 |
|
55.3 |
|
2.3% |
|
56.1 |
|
1.5% |
Pharmaceutical Synthesis
Pharmaceutical Synthesis generated
€89.1 million, up 0.2% compared to 2018 (-1.4% at a constant
exchange rates). Although operational difficulties mentioned during
the first semester have continued, indicators are heading in the
right direction. During the third quarter we still experienced
supply issues for certain raw materials, which caused certain
production to be postponed to the fourth quarter and possibly to
2020.
Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals totaled
€56.5 million, up 2.3% on 2018 (+1.5% at constant exchange
rates). Fine Chemicals and Electronics are still showing growth,
offsetting a slowdown with some Lubricants customers.
Outlook for the current year
Group net sales in 2019 are expected to be on a
par with the previous financial year, adversely affected by
operational difficulties that persisted throughout the first
9 months of the year in the Pharmaceutical Synthesis business,
and by a slowdown in our Lubricants business, all of which is
expected to affect the Group’s operating income which will thus be
lower than in 2018. For the record, the Group’s net income will
include the costs of reorganizing the Longjumeau site announced at
the end of 2018, which were recorded in the 2019 half-yearly
financial statements.
NEXT FINANCIAL DISCLOSURE:
Net sales in 2019, January 28, 2020
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 9% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €206.7 million in 2018 and employs close to 1 100
people in six countries.
To find out more about PCAS: www.pcas.com
PCAS |
Newcap |
Frédéric Desdouits / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier
NewCapFinancial communication and investor
relations |
Tel.: +33 1 69 79 61 32www.pcas.com |
Tel.: +33 1 44 71 98 53pcas@newcap.eu |
- PCAS_Net sales_September 30_2019_eng
PCAS (EU:PCA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
PCAS (EU:PCA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024